At Neurotar, we advance brain research in live mice, offering a more translational alternative to in vitro and ex vivo studies. We provide in vivo two-photon and wide-field imaging of the mouse brain as a service to global pharma and biotech companies focused on the CNS. Our key areas of expertise: • Brain delivery and biodistribution of large molecules • Synaptic plasticity and neuronal activity in health and disease • Neurodegeneration, neuroinflammation, and stroke In vivo two-photon imaging enables longitudinal studies at subcellular resolution, while wide-field imaging captures functional activity across the entire cortex. By imaging awake, head-fixed mice, we avoid anesthesia-related confounds and enhance the relevance of in vivo data. We also develop and commercialize innovative tools for basic research. Our Mobile HomeCage product line supports studies in awake, non-anesthetized mice, eliminating biases linked to anesthesia. The system integrates seamlessly with high-precision techniques like in vivo two-photon imaging, electrophysiology, and optogenetics, combined with behavioral assays. The Mobile HomeCage is trusted by 250+ academic and industrial labs worldwide, especially in North America and Central Europe. CNS drug developers - especially those working on biologics or psychoactive compounds - reach out to learn how Neurotar’s one-of-a-kind imaging assays can sharpen your lead optimization and candidate selection. Neuroscience labs - talk to us if you’re looking for a stable, versatile, and easy-to-use head-fixation solution for mice seamlessly integrated with a behavioral platform via a magnetic locomotion-tracking.
Looking for a particular Neurotar Oy Ltd employee's phone or email?
The Neurotar Oy Ltd annual revenue was $5.7 million in 2026.
Katja Karelina is the CEO of Neurotar Oy Ltd.
8 people are employed at Neurotar Oy Ltd.
Neurotar Oy Ltd is based in Helsinki, Uusimaa.
The NAICS codes for Neurotar Oy Ltd are [54, 54171, 5417, 541713, 541].
The SIC codes for Neurotar Oy Ltd are [873, 87].